[HTML][HTML] Next-generation treatments: Immunotherapy and advanced therapies for COVID-19
JA Arevalo-Romero, SM Chingaté-López, BA Camacho… - Heliyon, 2024 - cell.com
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), emerged in 2019 following prior outbreaks of coronaviruses like SARS and …
(SARS-CoV-2), emerged in 2019 following prior outbreaks of coronaviruses like SARS and …
SARS-CoV-2 evolution has increased resistance to monoclonal antibodies and first-generation COVID-19 vaccines: Is there a future therapeutic role for soluble ACE2 …
COVID-19 has caused calamitous health, economic and societal consequences. Although
several COVID-19 vaccines have received full authorization for use, global deployment has …
several COVID-19 vaccines have received full authorization for use, global deployment has …
[HTML][HTML] Disulfide Bond Engineering of Soluble ACE2 for Thermal Stability Enhancement
YS Kim, M Kim, HM Park, HJ Kim, SE Ryu - International Journal of …, 2024 - mdpi.com
Although the primary pandemic of SARS-CoV-2 is over, there are concerns about the
resurgence of the next wave of related viruses, including a wide range of variant viruses …
resurgence of the next wave of related viruses, including a wide range of variant viruses …
ACE2 decoy Fc-fusions and bi-specific killer engager (BiKEs) require Fc engagement for in vivo efficacy against SARS-CoV-2
SARS-CoV-2 virus has continued to evolve over time necessitating the adaptation of
vaccines to maintain efficacy. Monoclonal antibodies (mAbs) against SARS-CoV-2 were a …
vaccines to maintain efficacy. Monoclonal antibodies (mAbs) against SARS-CoV-2 were a …